| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydrocortisone | 58 | 2024 | 187 | 11.190 |
Why?
|
| Hair | 40 | 2023 | 78 | 6.710 |
Why?
|
| Macaca mulatta | 36 | 2024 | 228 | 4.710 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 17 | 2013 | 18 | 4.340 |
Why?
|
| Stress, Psychological | 22 | 2024 | 442 | 3.970 |
Why?
|
| Hypothalamo-Hypophyseal System | 20 | 2024 | 88 | 3.770 |
Why?
|
| Pituitary-Adrenal System | 19 | 2024 | 60 | 2.960 |
Why?
|
| Behavior, Animal | 19 | 2019 | 215 | 2.800 |
Why?
|
| Stress, Physiological | 15 | 2020 | 185 | 2.700 |
Why?
|
| Self-Injurious Behavior | 9 | 2021 | 45 | 2.120 |
Why?
|
| Alopecia | 6 | 2019 | 25 | 2.060 |
Why?
|
| Saliva | 11 | 2022 | 99 | 1.910 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 9 | 2013 | 23 | 1.630 |
Why?
|
| Neurotoxicity Syndromes | 5 | 2011 | 21 | 1.550 |
Why?
|
| Mother-Child Relations | 5 | 2020 | 43 | 1.540 |
Why?
|
| Prenatal Exposure Delayed Effects | 7 | 2024 | 151 | 1.500 |
Why?
|
| Animals | 73 | 2024 | 19601 | 1.310 |
Why?
|
| Serotonin Agents | 6 | 2013 | 10 | 1.300 |
Why?
|
| Mothers | 12 | 2020 | 255 | 1.220 |
Why?
|
| Rats | 21 | 2016 | 1909 | 1.190 |
Why?
|
| Fluorocarbons | 2 | 2024 | 34 | 1.110 |
Why?
|
| Hallucinogens | 6 | 2009 | 14 | 1.110 |
Why?
|
| Serotonin | 9 | 2012 | 59 | 1.080 |
Why?
|
| Rats, Sprague-Dawley | 17 | 2013 | 574 | 1.070 |
Why?
|
| Male | 73 | 2024 | 27727 | 1.060 |
Why?
|
| Female | 65 | 2024 | 30695 | 0.990 |
Why?
|
| Maternal Behavior | 4 | 2020 | 31 | 0.990 |
Why?
|
| Anxiety | 8 | 2019 | 387 | 0.970 |
Why?
|
| Nails | 4 | 2021 | 38 | 0.960 |
Why?
|
| Animals, Newborn | 11 | 2017 | 230 | 0.900 |
Why?
|
| Biomarkers | 8 | 2018 | 1305 | 0.890 |
Why?
|
| Cocaine | 6 | 2019 | 96 | 0.880 |
Why?
|
| Primates | 6 | 2020 | 42 | 0.840 |
Why?
|
| Body Temperature | 6 | 2013 | 45 | 0.820 |
Why?
|
| Pregnancy | 17 | 2024 | 2202 | 0.800 |
Why?
|
| Disease Models, Animal | 8 | 2024 | 2046 | 0.800 |
Why?
|
| Motor Activity | 7 | 2013 | 333 | 0.790 |
Why?
|
| Brain | 11 | 2024 | 1487 | 0.770 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2022 | 380 | 0.720 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 96 | 0.720 |
Why?
|
| Fever | 2 | 2011 | 61 | 0.710 |
Why?
|
| Callithrix | 3 | 2018 | 20 | 0.680 |
Why?
|
| Child, Preschool | 10 | 2022 | 1782 | 0.670 |
Why?
|
| Child | 15 | 2024 | 4173 | 0.630 |
Why?
|
| Cebus | 1 | 2018 | 1 | 0.610 |
Why?
|
| Lactation | 2 | 2015 | 66 | 0.600 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 13 | 0.590 |
Why?
|
| Humans | 45 | 2024 | 59282 | 0.580 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 175 | 0.570 |
Why?
|
| Aggression | 6 | 2019 | 52 | 0.550 |
Why?
|
| Students | 1 | 2019 | 202 | 0.550 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2019 | 806 | 0.550 |
Why?
|
| Refugees | 3 | 2024 | 66 | 0.540 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 65 | 0.540 |
Why?
|
| Sleep | 3 | 2021 | 215 | 0.540 |
Why?
|
| Social Behavior | 8 | 2019 | 87 | 0.530 |
Why?
|
| Cerebral Cortex | 3 | 2013 | 248 | 0.530 |
Why?
|
| Dronabinol | 2 | 2011 | 31 | 0.530 |
Why?
|
| Emotions | 3 | 2019 | 214 | 0.520 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 9 | 0.510 |
Why?
|
| Monkey Diseases | 3 | 2019 | 7 | 0.490 |
Why?
|
| Infant | 10 | 2023 | 1486 | 0.470 |
Why?
|
| Body Weight | 8 | 2013 | 368 | 0.470 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 259 | 0.460 |
Why?
|
| Social Class | 3 | 2020 | 122 | 0.450 |
Why?
|
| Endocrine System Diseases | 1 | 2014 | 10 | 0.450 |
Why?
|
| Neuropsychiatry | 1 | 2014 | 9 | 0.440 |
Why?
|
| Attention | 5 | 2019 | 146 | 0.440 |
Why?
|
| Dopamine | 2 | 2012 | 102 | 0.440 |
Why?
|
| Protein Binding | 5 | 2012 | 1554 | 0.420 |
Why?
|
| Mood Disorders | 1 | 2014 | 69 | 0.420 |
Why?
|
| Brain Chemistry | 3 | 2009 | 77 | 0.420 |
Why?
|
| Age Factors | 8 | 2019 | 1504 | 0.410 |
Why?
|
| Environmental Pollutants | 2 | 2024 | 91 | 0.410 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2012 | 34 | 0.400 |
Why?
|
| Mindfulness | 2 | 2024 | 66 | 0.390 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 81 | 0.390 |
Why?
|
| Citalopram | 3 | 2011 | 19 | 0.390 |
Why?
|
| Mental Disorders | 2 | 2022 | 717 | 0.390 |
Why?
|
| Phenotype | 1 | 2016 | 1136 | 0.390 |
Why?
|
| Analysis of Variance | 8 | 2016 | 589 | 0.380 |
Why?
|
| Fear | 4 | 2022 | 65 | 0.370 |
Why?
|
| Hydroxyindoleacetic Acid | 5 | 2012 | 11 | 0.360 |
Why?
|
| Adolescent | 11 | 2024 | 5822 | 0.350 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2009 | 2 | 0.340 |
Why?
|
| Carbolines | 1 | 2009 | 9 | 0.330 |
Why?
|
| Social Environment | 4 | 2016 | 91 | 0.330 |
Why?
|
| Progesterone | 2 | 2015 | 158 | 0.330 |
Why?
|
| Cheirogaleidae | 1 | 2009 | 6 | 0.330 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2009 | 30 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 2059 | 0.320 |
Why?
|
| Models, Animal | 2 | 2014 | 221 | 0.320 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2008 | 2 | 0.310 |
Why?
|
| Amphetamines | 1 | 2008 | 5 | 0.310 |
Why?
|
| Body Temperature Regulation | 2 | 2005 | 20 | 0.310 |
Why?
|
| Reproduction | 1 | 2009 | 89 | 0.310 |
Why?
|
| Sex Factors | 7 | 2024 | 935 | 0.310 |
Why?
|
| Neurosecretory Systems | 1 | 2008 | 24 | 0.310 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2024 | 12 | 0.310 |
Why?
|
| Adult | 14 | 2024 | 15663 | 0.300 |
Why?
|
| Estradiol | 1 | 2009 | 247 | 0.290 |
Why?
|
| Memory Disorders | 2 | 2005 | 48 | 0.290 |
Why?
|
| Testosterone | 4 | 2019 | 112 | 0.290 |
Why?
|
| Neurotoxins | 2 | 2010 | 20 | 0.290 |
Why?
|
| Time Factors | 8 | 2012 | 3614 | 0.290 |
Why?
|
| Social Dominance | 3 | 2019 | 4 | 0.280 |
Why?
|
| Pilot Projects | 4 | 2024 | 914 | 0.280 |
Why?
|
| Child Development | 5 | 2023 | 79 | 0.280 |
Why?
|
| Locomotion | 1 | 2008 | 111 | 0.280 |
Why?
|
| Membrane Transport Proteins | 2 | 2004 | 120 | 0.270 |
Why?
|
| Glucocorticoids | 3 | 2023 | 179 | 0.270 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2006 | 5 | 0.260 |
Why?
|
| Neostriatum | 2 | 2009 | 25 | 0.260 |
Why?
|
| Mental Health | 3 | 2024 | 335 | 0.250 |
Why?
|
| Serotonin Syndrome | 1 | 2005 | 9 | 0.250 |
Why?
|
| Extinction, Psychological | 2 | 2004 | 14 | 0.250 |
Why?
|
| Parents | 3 | 2019 | 367 | 0.250 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 292 | 0.240 |
Why?
|
| Young Adult | 8 | 2024 | 4266 | 0.240 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 416 | 0.240 |
Why?
|
| Housing, Animal | 5 | 2016 | 12 | 0.240 |
Why?
|
| Corticosterone | 3 | 2016 | 22 | 0.240 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2024 | 2 | 0.230 |
Why?
|
| Hyperthermia, Induced | 1 | 2004 | 18 | 0.230 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 660 | 0.230 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2024 | 20 | 0.230 |
Why?
|
| Social Support | 2 | 2024 | 355 | 0.220 |
Why?
|
| Fenfluramine | 1 | 2003 | 4 | 0.220 |
Why?
|
| Amniotic Fluid | 1 | 2023 | 8 | 0.220 |
Why?
|
| Infant, Newborn | 5 | 2023 | 1283 | 0.220 |
Why?
|
| Sex Characteristics | 3 | 2020 | 197 | 0.220 |
Why?
|
| Environment | 3 | 2016 | 119 | 0.220 |
Why?
|
| Phthalic Acids | 1 | 2024 | 36 | 0.220 |
Why?
|
| Reaction Time | 5 | 2019 | 119 | 0.210 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 200 | 0.210 |
Why?
|
| Reflex, Startle | 1 | 2002 | 7 | 0.200 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2019 | 23 | 0.200 |
Why?
|
| Animal Welfare | 2 | 2019 | 10 | 0.200 |
Why?
|
| Farmers | 1 | 2022 | 19 | 0.200 |
Why?
|
| Conditioning, Classical | 1 | 2002 | 5 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 33 | 0.190 |
Why?
|
| Maternal Deprivation | 3 | 2024 | 3 | 0.190 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 207 | 0.190 |
Why?
|
| Father-Child Relations | 1 | 2021 | 8 | 0.190 |
Why?
|
| Paternal Behavior | 1 | 2021 | 6 | 0.190 |
Why?
|
| Fathers | 1 | 2021 | 21 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 89 | 0.180 |
Why?
|
| Exploratory Behavior | 3 | 2011 | 33 | 0.180 |
Why?
|
| Receptors, Drug | 1 | 2000 | 5 | 0.180 |
Why?
|
| Poverty | 2 | 2020 | 281 | 0.180 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2000 | 7 | 0.180 |
Why?
|
| Receptors, Opioid, delta | 1 | 2000 | 5 | 0.180 |
Why?
|
| Receptors, Opioid, mu | 1 | 2000 | 14 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 107 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2373 | 0.170 |
Why?
|
| Amygdala | 1 | 2020 | 78 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 283 | 0.170 |
Why?
|
| Nucleus Accumbens | 1 | 2000 | 42 | 0.170 |
Why?
|
| Placenta | 1 | 2020 | 55 | 0.170 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 107 | 0.170 |
Why?
|
| Grooming | 2 | 2017 | 4 | 0.170 |
Why?
|
| Abattoirs | 1 | 2019 | 2 | 0.170 |
Why?
|
| White Matter | 1 | 2021 | 114 | 0.170 |
Why?
|
| Animal Husbandry | 1 | 2019 | 9 | 0.170 |
Why?
|
| Aging | 4 | 2009 | 710 | 0.170 |
Why?
|
| Dopamine Agonists | 1 | 1999 | 20 | 0.160 |
Why?
|
| Reinforcement Schedule | 1 | 2019 | 8 | 0.160 |
Why?
|
| Meat | 1 | 2019 | 33 | 0.160 |
Why?
|
| Attentional Bias | 1 | 2019 | 1 | 0.160 |
Why?
|
| Benzazepines | 1 | 1999 | 21 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 328 | 0.160 |
Why?
|
| Sexual Maturation | 1 | 2019 | 50 | 0.160 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2019 | 33 | 0.160 |
Why?
|
| ROC Curve | 1 | 2019 | 266 | 0.160 |
Why?
|
| Diazepam | 2 | 2011 | 10 | 0.150 |
Why?
|
| Parent-Child Relations | 1 | 2019 | 57 | 0.150 |
Why?
|
| Neurons | 1 | 2004 | 863 | 0.150 |
Why?
|
| Swine | 1 | 2019 | 352 | 0.150 |
Why?
|
| Child Behavior | 1 | 2019 | 63 | 0.150 |
Why?
|
| Anti-Anxiety Agents | 2 | 2011 | 31 | 0.150 |
Why?
|
| Tetanus Toxoid | 1 | 2018 | 14 | 0.150 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2018 | 11 | 0.150 |
Why?
|
| Interpersonal Relations | 2 | 2011 | 150 | 0.150 |
Why?
|
| Serbia | 3 | 2024 | 3 | 0.150 |
Why?
|
| Binding, Competitive | 2 | 2010 | 97 | 0.150 |
Why?
|
| Universities | 1 | 2019 | 144 | 0.150 |
Why?
|
| Hippocampus | 2 | 2010 | 246 | 0.150 |
Why?
|
| Telomere | 1 | 2017 | 50 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 19 | 0.140 |
Why?
|
| Cushing Syndrome | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antibodies, Bacterial | 1 | 2018 | 186 | 0.140 |
Why?
|
| Milk | 1 | 2017 | 39 | 0.140 |
Why?
|
| Impulsive Behavior | 1 | 2017 | 28 | 0.140 |
Why?
|
| Macaca nemestrina | 1 | 2016 | 8 | 0.140 |
Why?
|
| Ejaculation | 2 | 2007 | 8 | 0.130 |
Why?
|
| Self Report | 1 | 2019 | 359 | 0.130 |
Why?
|
| Prolactin | 2 | 2008 | 40 | 0.130 |
Why?
|
| Maze Learning | 2 | 2007 | 50 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2016 | 42 | 0.130 |
Why?
|
| Death | 1 | 2016 | 25 | 0.130 |
Why?
|
| Perception | 1 | 2017 | 167 | 0.130 |
Why?
|
| Parenting | 1 | 2016 | 67 | 0.130 |
Why?
|
| Growth and Development | 1 | 2015 | 8 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 483 | 0.120 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2015 | 9 | 0.120 |
Why?
|
| Hormones | 1 | 2015 | 60 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1561 | 0.120 |
Why?
|
| Parity | 1 | 2015 | 70 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2511 | 0.110 |
Why?
|
| Animal Communication | 1 | 2014 | 4 | 0.110 |
Why?
|
| Solid Phase Extraction | 1 | 2014 | 9 | 0.110 |
Why?
|
| Random Allocation | 4 | 2019 | 192 | 0.110 |
Why?
|
| Postpartum Period | 1 | 2016 | 182 | 0.110 |
Why?
|
| Middle Aged | 5 | 2024 | 16310 | 0.110 |
Why?
|
| Oxytocin | 1 | 2014 | 45 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 677 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 364 | 0.110 |
Why?
|
| Exercise | 1 | 2020 | 883 | 0.110 |
Why?
|
| Species Specificity | 1 | 2014 | 328 | 0.100 |
Why?
|
| Resilience, Psychological | 1 | 2014 | 55 | 0.100 |
Why?
|
| Child Abuse | 1 | 2014 | 89 | 0.100 |
Why?
|
| Electroshock | 2 | 2002 | 3 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 456 | 0.100 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2011 | 14 | 0.090 |
Why?
|
| Memory, Short-Term | 1 | 2011 | 59 | 0.090 |
Why?
|
| Hair Preparations | 1 | 2010 | 2 | 0.090 |
Why?
|
| Memory | 2 | 2009 | 111 | 0.090 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 6 | 0.090 |
Why?
|
| Baths | 1 | 2010 | 7 | 0.090 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 2009 | 3 | 0.080 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2009 | 3 | 0.080 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Synaptosomes | 1 | 2009 | 16 | 0.080 |
Why?
|
| Methamphetamine | 1 | 2009 | 22 | 0.080 |
Why?
|
| Concept Formation | 1 | 2009 | 17 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 127 | 0.080 |
Why?
|
| Benzylamines | 1 | 2009 | 30 | 0.080 |
Why?
|
| Madagascar | 1 | 2009 | 4 | 0.080 |
Why?
|
| Drug Interactions | 3 | 2011 | 115 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 141 | 0.080 |
Why?
|
| Androgens | 1 | 2009 | 47 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 63 | 0.080 |
Why?
|
| Nerve Fibers | 1 | 2009 | 29 | 0.080 |
Why?
|
| Ketanserin | 1 | 2008 | 1 | 0.080 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2008 | 1 | 0.080 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2008 | 8 | 0.080 |
Why?
|
| Feces | 1 | 2009 | 97 | 0.080 |
Why?
|
| Water | 1 | 2010 | 300 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2022 | 525 | 0.080 |
Why?
|
| Transcortin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 365 | 0.070 |
Why?
|
| Health Promotion | 2 | 2022 | 471 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 846 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 741 | 0.070 |
Why?
|
| Leuprolide | 3 | 2011 | 14 | 0.070 |
Why?
|
| Gene Expression | 1 | 2009 | 808 | 0.070 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2006 | 2 | 0.060 |
Why?
|
| Depression | 3 | 2018 | 828 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2011 | 86 | 0.060 |
Why?
|
| Stereotypic Movement Disorder | 1 | 2005 | 1 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2005 | 29 | 0.060 |
Why?
|
| Cognition | 1 | 2009 | 455 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 74 | 0.060 |
Why?
|
| Pyridines | 1 | 2006 | 98 | 0.060 |
Why?
|
| Neurochemistry | 1 | 2005 | 2 | 0.060 |
Why?
|
| Macaca | 1 | 2005 | 29 | 0.060 |
Why?
|
| Photic Stimulation | 2 | 2019 | 89 | 0.060 |
Why?
|
| Borderline Personality Disorder | 1 | 2005 | 14 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2004 | 37 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2005 | 79 | 0.060 |
Why?
|
| Refugee Camps | 1 | 2024 | 2 | 0.060 |
Why?
|
| Catecholamines | 1 | 2004 | 29 | 0.060 |
Why?
|
| Kenya | 1 | 2024 | 79 | 0.060 |
Why?
|
| Amniocentesis | 1 | 2023 | 5 | 0.060 |
Why?
|
| Models, Biological | 2 | 2008 | 1140 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 206 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1093 | 0.050 |
Why?
|
| Mice | 2 | 2014 | 10251 | 0.050 |
Why?
|
| Skin | 1 | 2006 | 357 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2004 | 201 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2024 | 143 | 0.050 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2002 | 5 | 0.050 |
Why?
|
| Homovanillic Acid | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genes, fos | 1 | 2002 | 18 | 0.050 |
Why?
|
| Peer Group | 2 | 2016 | 95 | 0.050 |
Why?
|
| Bhutan | 1 | 2022 | 20 | 0.050 |
Why?
|
| Acoustic Stimulation | 1 | 2002 | 50 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2016 | 485 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 208 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2002 | 182 | 0.050 |
Why?
|
| Congo | 1 | 2021 | 1 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 682 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 424 | 0.050 |
Why?
|
| United States | 1 | 2014 | 7385 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2018 | 2372 | 0.050 |
Why?
|
| Papio | 1 | 2020 | 12 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 229 | 0.050 |
Why?
|
| Phencyclidine | 1 | 2000 | 3 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 69 | 0.040 |
Why?
|
| Sulfur Isotopes | 1 | 2000 | 3 | 0.040 |
Why?
|
| Actigraphy | 1 | 2021 | 47 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 178 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2020 | 95 | 0.040 |
Why?
|
| Nervous System | 1 | 2000 | 69 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 43 | 0.040 |
Why?
|
| Weaning | 1 | 1999 | 8 | 0.040 |
Why?
|
| Videotape Recording | 1 | 1999 | 46 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 46 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 231 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2000 | 141 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2019 | 82 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 1094 | 0.040 |
Why?
|
| Problem Behavior | 1 | 2017 | 12 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 716 | 0.040 |
Why?
|
| Family Relations | 1 | 2017 | 21 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 373 | 0.040 |
Why?
|
| Fixation, Ocular | 1 | 2017 | 32 | 0.030 |
Why?
|
| Hydroxysteroids | 1 | 2017 | 1 | 0.030 |
Why?
|
| Play and Playthings | 1 | 2017 | 20 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1137 | 0.030 |
Why?
|
| Territoriality | 1 | 2016 | 1 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 3065 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1032 | 0.030 |
Why?
|
| Oregon | 1 | 2016 | 19 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 164 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 54 | 0.030 |
Why?
|
| Dermis | 1 | 2016 | 16 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 186 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 179 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 362 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2016 | 45 | 0.030 |
Why?
|
| Anesthesia | 1 | 2016 | 48 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 379 | 0.030 |
Why?
|
| Anemia, Neonatal | 1 | 2015 | 3 | 0.030 |
Why?
|
| Vaccination | 1 | 2018 | 333 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 1547 | 0.030 |
Why?
|
| Life Change Events | 1 | 2015 | 65 | 0.030 |
Why?
|
| Imitative Behavior | 1 | 2014 | 7 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1479 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 143 | 0.030 |
Why?
|
| Oxytocics | 1 | 2014 | 14 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 145 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1189 | 0.030 |
Why?
|
| Facial Expression | 1 | 2011 | 16 | 0.020 |
Why?
|
| Fluoxetine | 1 | 2011 | 44 | 0.020 |
Why?
|
| Avoidance Learning | 1 | 2010 | 23 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 133 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2337 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 78 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2009 | 8 | 0.020 |
Why?
|
| Visual Perception | 1 | 2009 | 41 | 0.020 |
Why?
|
| Mental Recall | 1 | 2009 | 88 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 153 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 868 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 185 | 0.020 |
Why?
|
| Orientation | 1 | 2008 | 27 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 617 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 715 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 371 | 0.020 |
Why?
|
| Movement | 1 | 2008 | 149 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1025 | 0.020 |
Why?
|
| Consciousness | 1 | 2006 | 12 | 0.020 |
Why?
|
| Laboratory Animal Science | 1 | 2005 | 1 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 2005 | 10 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 976 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2006 | 228 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 445 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 356 | 0.010 |
Why?
|
| Reward | 1 | 2004 | 83 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1236 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 6071 | 0.010 |
Why?
|